MedTrace Logo

An Observational Study Investigating the Treatment Satisfaction of Atopic Dermatitis Patients Who Have Switched to Ointment (W/O Emulsion) Formulation of Very Strong Class Topical Corticosteroids

NCT02627989 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 55

Last updated 2020-04-01

No results posted yet for this study

Summary

This study intends to investigate patient satisfaction of treatment with Ointment (W/O emulsion) formulations of Potency Class II topical corticosteroids (TCs) for atopic dermatitis (AD) patients in Japan. Objectives include measuring patient satisfaction, treatment adherence, itchiness, and AD severity scores.

Conditions

  • Dermatitis, Atopic

Interventions

DRUG

Diflucortolone valerate (Nerisona)

Potency Class II (classified as Very Strong class in Japan) topical corticosteroids

DRUG

Diflucortolone valerate (Texmeten)

Potency Class II (classified as Very Strong class in Japan) topical corticosteroids

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • LEO Pharma

    lead INDUSTRY

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-10
Primary Completion
2016-11-17
Completion
2017-01-17

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02627989 on ClinicalTrials.gov